The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under ...

Oral presentation to highlight updated Phase 1 monotherapy safety and efficacy data for TOS-358, a covalent PI3Ka inhibitorData will include ...

Although significant progress has been made in the treatment and management of patients with FL, several challenges remain, including the need to develop better prognostic models and markers for ...

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...

The enzyme PI3K plays a critical role in cell migration. Scientists have long understood this function. But researchers have recently unveiled that a subunit of this enzyme also has the ability to ...

ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...

After noticing concerning patient survival data across multiple clinical trials, the FDA is losing confidence in the safety profile of the notoriously toxic PI3K inhibitor drug class for blood cancers ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

Abbreviations: 4EBP1, 4E binding protein 1; BCL-2, B-cell lymphoma 2; EEF2K, eukaryotic elongation factor-2 kinase; EIF4B, eukaryotic translation initiation factor 4B; ERK, extracellular ...